| 000 | 01612 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516170321.0 | ||
| 264 | 0 | _c20140507 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1879-114X | ||
| 024 | 7 |
_a10.1016/j.clinthera.2013.08.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDevos, David | |
| 245 | 0 | 0 |
_aNew pharmacological options for treating advanced Parkinson's disease. _h[electronic resource] |
| 260 |
_bClinical therapeutics _cOct 2013 |
||
| 300 |
_a1640-52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aApathy _xdrug effects |
| 650 | 0 | 4 |
_aCholinesterase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDeep Brain Stimulation |
| 650 | 0 | 4 |
_aDopamine Plasma Membrane Transport Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDopamine Uptake Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Discovery |
| 650 | 0 | 4 |
_aGait _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIron Chelating Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aMethylphenidate _xtherapeutic use |
| 650 | 0 | 4 |
_aNorepinephrine Plasma Membrane Transport Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, N-Methyl-D-Aspartate _xantagonists & inhibitors |
| 700 | 1 | _aMoreau, Caroline | |
| 700 | 1 | _aDujardin, Kathy | |
| 700 | 1 | _aCabantchik, Ioav | |
| 700 | 1 | _aDefebvre, Luc | |
| 700 | 1 | _aBordet, Regis | |
| 773 | 0 |
_tClinical therapeutics _gvol. 35 _gno. 10 _gp. 1640-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clinthera.2013.08.011 _zAvailable from publisher's website |
| 999 |
_c23066146 _d23066146 |
||